Relapsed or Refractory CD30+ Hodgkin's Lymphoma or Anaplastic Large Cell Lymphoma

1 clinical trials · Condition

Record	Firm	Date
Brentuximab Vedotin (Recombinant) for IV Infusion - Special Drug Use Surveillance (All-case Surveillance) "Relapsed or Refractory CD30+ Hodgkin's Lymphoma or Anaplastic Large Cell Lymphoma" (NCT02139592)	Takeda	2014-04-17

Every clearance here is in the API, with alerts when new ones post.